KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Equivalents (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Cash & Equivalents for 16 consecutive years, with $133.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 15.51% to $133.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $133.8 million, a 15.51% increase, with the full-year FY2025 number at $133.8 million, up 15.51% from a year prior.
  • Cash & Equivalents was $133.8 million for Q4 2025 at Halozyme Therapeutics, down from $419.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $419.7 million in Q3 2025 to a low of $90.9 million in Q2 2022.
  • A 5-year average of $191.3 million and a median of $144.1 million in 2024 define the central range for Cash & Equivalents.
  • Biggest YoY gain for Cash & Equivalents was 171.95% in 2025; the steepest drop was 49.72% in 2025.
  • Halozyme Therapeutics' Cash & Equivalents stood at $118.7 million in 2021, then surged by 97.27% to $234.2 million in 2022, then tumbled by 49.46% to $118.4 million in 2023, then dropped by 2.13% to $115.8 million in 2024, then rose by 15.51% to $133.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Cash & Equivalents are $133.8 million (Q4 2025), $419.7 million (Q3 2025), and $176.3 million (Q1 2025).